(Reuters) - Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters
Italy blocked the export of AstraZeneca PLC’s Covid-19 vaccine to Australia, according to people familiar with the matter, in a move coordinated with European Union authorities, reflecting mounting frustration in Europe with slow deliveries of vaccines.
Canada's Liberal Govt said Monday it would ignore the advice of a top panel of scientists that recommended the Covid-19 vaccine from AstraZeneca PLC, in partnership with Oxford University, not be administered to people 65 years of age and older.
AstraZeneca Plc has sold its 7.7% stake in Moderna Inc for more than $1 billion after the US biotechnology company’s shares soared on the back of its coronavirus vaccine breakthrough, the Times reported.
Australia received 300,000 doses of the AstraZeneca PLC vaccine on Sunday, more than doubling the amount of all vaccines shipped to the country so far and allowing the government to ramp up its COVID-19 immunization drive.
JUST IN: A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen
A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.
Read more about the vaccine here: